Studies on the Neutralizing Effects of Protamine on Unfractionated and Low Molecular Weight Heparin (Fragmin®) at the Site of Activation of the Coagulation System in Man

Summary

In a double-blind, randomized, cross-over study the neutralizing action of protamine towards unfractionated heparin (UFH, 150 U/kg i.v.) and a low molecular weight heparin (LMWH, Fragmin®, 100 anti-Xa U/kg i.v.) was investigated in 15 healthy subjects in vitro by measuring activated partial thromboplastin time (APTT), thrombin time (TT) and anti factor Xa activity (anti-Xa) in venous blood and in vivo by determination of prothrombin fragment 1.2 (f1.2) and thrombin-antithrombin III complexes (TAT) in venous blood and in shed blood. UFH and LMWH caused a prolongation of APTT and TT, an increase in anti-Xa and significantly inhibited f1.2 and TAT formation in shed blood, whereas only a minimal effect on TAT and f1.2 formation in venous blood was noted. Administration of 1 mg protamine/100 U UFH resulted in a near complete reversal of APTT, TT and anti-Xa, whereas lower doses (0.25 and 0.5 mg) were less effective. The effects of UFH on f1.2 and TAT generation in shed blood were partially (60-70%) neutralized only by the high dose (1.0 mg). Application of 1 mg protamine/100 anti-Xa U LMWH caused a near complete reversal of both APTT and TT but had only a weak effect on anti-Xa. In shed blood, the effect of LMWH on TAT and f1.2 formation was reversed by protamine only by 14% and 23% respectively. Our data do not support the concept that to reduce the incidence of protamine’s potential clinical side effects, the administration of a lower dose of protamine than 1 mg protamine/100 U UFH is justified. Furthermore, a significant residual impairment of hemostasis is still detectable after administration of the recommended dose of protamine to neutralize the anticoagulant effects of a LMWH preparation.

• References

• 1 Okajima Y, Kanayama S, Maeda Y, Urano S, Kitani T, Watada M, Nakagawa M, Ijichi H. Studies on the neutralizing mechanism of antithrombin activity of heparin by protamine. Thromb Res 1981; 24: 21-29
• 2 Jones GR, Hashim R, Power DM. A comparison of the strength of binding of antithrombin III, protamine and poly(L-lysine) to heparin samples of dif-ferent anticoagulant activities. Biochem Biophys Acta 1986; 883: 69-76
• 3 Kuitunen AH, Salmenpera MT, Heinonen J, Rasi VP, Myllyla G. Heparin rebound: a comparative study of protamine chloride and protamine sulfate in patients undergoing coronary artery bypass surgery. J Cardiothorac Vase Anesth 1991; 5: 221-226
• 4 Walton PL, Ricketts CR, Bangham DR. Heterogeneity of heparin. Brit J Haematol 1966; 12: 310-325
• 5 Berger RL, Ramaswamy K, Ryan TJ. Reduced protamine dosage for heparin neutralization in open-heart operations. Circulation 1968; 37 suppl 2: 154-157
• 6 Lowary LR, Smith FA, Coyne E, Dunham NW. Comparative neutralization of lung- and mucosal-derived heparin by protamine sulfate using in vitro and in vivo methods. J Pharm Sci 1971; 60: 638-640
• 7 Graham DT, Pomeroy AR, Smythe DB. Measurement of the heparin neutralizing capacity of protamine. Thromb Haemostas 1979; 41: 583-589
• 8 Hobbhahn J, Conzen PF, Habazettl H, Gutmann R, Kellermann W, Peter K. Heparin reversal by protamine in humans - complement, prostaglandins, blood cells, and hemodynamics. J Appl Physiol 1991; 71: 1415-1421
• 9 Montalescot G, Lowenstein E, Ogletree ML, Greene EM, Robinson DR, Hartl K, Zapol WM. Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep. Circulation 1990; 82: 1765-1777
• 10 Pearson PJ, Evora PR, Ayrancioglu K, Schaff HV H. Protamine releases endothelium-derived relaxing factor from systemic arteries. A possible mechanism of hypotension during heparin neuralization Circulation 1992; 86: 289-294
• 11 Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med 1993; 117: 71-77
• 12 Mielke CH, Kaneshiro MM, Mahler IA, Weiner J, Rapaport SI. The standardized Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-215
• 13 Kyrie PA, Eichler HG, Jäger U, Lechner K. Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo. Circulation 1987; 75: 1025-1029
• 14 Kyrie PA, Westwick J, Scully MF, Kakkar VV, Lewis GP. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man - effect of low-dose aspirin. Thromb Haemost 1987; 57: 62-66
• 15 Eichinger S, Wolzt M, Nieszpaur-Los M, Schneider B, Lechner K, Eichler HG, Kyrie PA. Effects of a low molecular weight heparin (Fragmin^®) and of unfractionated heparin on coagulation and platelet activation at the site of plug formation in vivo. Thromb Haemost 1994; 72: 831-835
• 16 Wolzt M, Eichinger S, Schneider B, Heinrichs H, Lechner K, Eichler HG, Kyrie PA. Effects of recombinant hirudin (r-hirudin; HBW 023) on the coagulation and platelet activation in vivo: comparison to unfractionated heparin and a low molecular weight heparin preparation (Fragmin^®). Eur J Clin Pharmacol 1994; 47: 120 A [abstract]
• 17 Racanelli A, Fareed J, Walenga JM, Coyne E. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions, and fragments. Semin Thromb Haemost 1985; 11: 176-90
• 18 Gram J, Mercker S, Bruhn HD. Does protamine chloride neutralize low molecular weight heparin sufficiently. Thromb Res 1988; 52: 353-359
• 19 Hubbard AR, Jennings CA. Neutralisation of heparan sulphate and low molecular weight heparin by protamine. Thromb Haemost 1985; 53: 86-89
• 20 Sugiyama T, Itoh M, Ohtawa M, Natsuga T. Study on neutralization of low molecular weight heparin (LHG) by protamine sulfate and its neutralization characteristics. Thromb Res 1992; 68: 119-129
• 21 Hirsh J, Buchanan MR. Comparative effects of heparin and LMW heparin on hemostasis. Thromb Res Comparative effects of heparin and LMW heparin on hemostasis 1991; 14 (Suppl) 11-17
• 22 Van Ryn-McKennaJ, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 1990; 63: 271-274
• 23 Diness V, Østergaard PB. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats. Thromb Haemostas 1986; 56: 318-322
• 24 Wright SJ, Murray WB, Hampton WA, Hargovan H. Calculating the protamine-heparin reversal ratio: a pilot study investigating a new method. J Cardiothorac Vase Anesth 1993; 7: 416-421
• 25 Massonnet-Castel S, Pelissier E, Bara L, Terrier E, Abry B, Guibourt P, Swanson J, Jaulmes B, Carpentier A, Samama M. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16: 139-146
• 26 Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J. Inhibition of low molecular weight heparin by protamine chloride in vivo. Thromb Res 1985; 38: 11-20
• 27 Albada J, Nieuwenhuis HK, Sixma JJ. Pharmacokinetics of a low molecular weight heparin (Kabi 2165, Fragmin) after intravenous and subcutaneous administration in human volunteers and its in vivo neutralization by protamine sulfate. Thromb Haemost 1988; 58: 17 [abstract]
• 28 Weiss HJ, Lages B. Evidence of tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 3: 629-635